{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:06:05Z","timestamp":1789142765869,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06765-8","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:07:35Z","timestamp":1789139255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma"],"prefix":"10.1007","volume":"44","author":[{"given":"Yuto","family":"Matsushita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimpei","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hoshina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Obinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kakutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Shiozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyo","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nishimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"6765_CR1","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL et al (2021) Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 384:1125\u20131135","journal-title":"N Engl J Med"},{"key":"6765_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL et al (2023) EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol 34:1047\u20131054","journal-title":"Ann Oncol"},{"key":"6765_CR3","unstructured":"Antoine G, van der Heijden HMB, Aitziber Carri\u00f3n R, Cathomas EM, Comp\u00e9rat K, Dimitropoulos JA, Efstathiou (2025) EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Available from: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer\/chapter\/citation-information. Accessed: 28 February 2026"},{"key":"6765_CR4","unstructured":"Thomas W, Flaig PES, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK Kevin Chan. (2025) NCCN Guidelines Bladder Cancer Version 3.2025. Accessed: 28 February 2026"},{"key":"6765_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cncr.34057","volume":"128","author":"VS Koshkin","year":"2022","unstructured":"Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A et al (2022) Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer 128:1194\u20131205","journal-title":"Cancer"},{"key":"6765_CR6","doi-asserted-by":"publisher","first-page":"102278","DOI":"10.1016\/j.clgc.2024.102278","volume":"23","author":"D Niedersuess-Beke","year":"2025","unstructured":"Niedersuess-Beke D, Mayrhofer K, Krauter J, Schnabel S, Gampenrieder SP, Miechowiecki J et al (2025) Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study. Clin Genitourin Cancer 23:102278","journal-title":"Clin Genitourin Cancer"},{"key":"6765_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/iju.15368","volume":"31","author":"W Fukuokaya","year":"2024","unstructured":"Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T et al (2024) Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study. Int J Urol 31:342\u2013347","journal-title":"Int J Urol"},{"key":"6765_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","volume":"53","author":"S Zschabitz","year":"2023","unstructured":"Zschabitz S, Biernath N, Hilser T, Hollein A, Zengerling F, Cascucelli J et al (2023) Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort. Eur Urol Open Sci 53:31\u201337","journal-title":"Eur Urol Open Sci"},{"key":"6765_CR9","doi-asserted-by":"publisher","first-page":"175628722514129","DOI":"10.1177\/17562872251412927","volume":"18","author":"M Catalano","year":"2026","unstructured":"Catalano M, Bartoli S, Salfi A, Bonalda M, Della Seta L, Paulet A et al (2026) Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification. Ther Adv Urol 18:17562872251412927","journal-title":"Ther Adv Urol"},{"key":"6765_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/iju.15435","volume":"31","author":"T Hara","year":"2024","unstructured":"Hara T, Matsushita Y, Harada K, Fujimoto N, Fujisawa M, Miyake H (2024) Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan. Int J Urol 31:696\u2013698","journal-title":"Int J Urol"},{"key":"6765_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15300","volume":"30","author":"S Taguchi","year":"2023","unstructured":"Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J et al (2023) Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. Int J Urol 30:1180\u20131186","journal-title":"Int J Urol"},{"key":"6765_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3390\/cancers16091725","volume":"16","author":"T Morikawa","year":"2024","unstructured":"Morikawa T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T et al (2024) C-Reactive protein is a potential prognostic marker in patient with advanced or metastatic urothelial carcinoma treated with enfortumab vedotin: a multi-center retrospective study. Cancers 16:1725","journal-title":"Cancers"},{"key":"6765_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/jjco\/hyad172","volume":"54","author":"S Taguchi","year":"2024","unstructured":"Taguchi S, Kawai T, Nakagawa T, Kume H (2024) Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review. Jpn J Clin Oncol 54:254\u2013264","journal-title":"Jpn J Clin Oncol"},{"key":"6765_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.eururo.2025.04.008","volume":"88","author":"CE Chu","year":"2025","unstructured":"Chu CE, Chen Z, Whiting K, Ostrovnaya I, Lenis AT, Clinton TN et al (2025) Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma. Eur Urol 88:472\u2013481","journal-title":"Eur Urol"},{"key":"6765_CR15","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850\u20131855","journal-title":"J Clin Oncol"},{"key":"6765_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.21873\/cdp.10396","volume":"4","author":"G Ishikawa","year":"2024","unstructured":"Ishikawa G, Matsushita Y, Kitagawa Y, Uchiyama A, Oishi Y, Tanaka H et al (2024) Risk Classification of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin. Cancer Diagn Progn 4:783\u2013788","journal-title":"Cancer Diagn Progn"},{"key":"6765_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/curroncol31020064","volume":"31","author":"A Minato","year":"2024","unstructured":"Minato A, Furubayashi N, Nagata Y, Tomoda T, Masaoka H, Song Y et al (2024) Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study. Curr Oncol 31:862\u2013871","journal-title":"Curr Oncol"},{"key":"6765_CR18","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1002\/cncr.35465","volume":"130","author":"DJ Martini","year":"2024","unstructured":"Martini DJ, Case KB, Gratz D, Pellegrini K, Beagle E, Schneider T et al (2024) PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation. Cancer 130:3658\u20133670","journal-title":"Cancer"},{"key":"6765_CR19","doi-asserted-by":"publisher","first-page":"12733","DOI":"10.1038\/srep12733","volume":"5","author":"L Zhou","year":"2015","unstructured":"Zhou L, Cai X, Liu Q, Jian ZY, Li H, Wang KJ (2015) Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis. Sci Rep 5:12733","journal-title":"Sci Rep"},{"key":"6765_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JOP.2016.011155","volume":"12","author":"W Goldner","year":"2016","unstructured":"Goldner W (2016) Cancer-Related Hypercalcemia. J Oncol Pract 12:426\u2013432","journal-title":"J Oncol Pract"},{"key":"6765_CR21","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794\u20135799","journal-title":"J Clin Oncol"},{"key":"6765_CR22","first-page":"470890","volume":"2013","author":"K Asao","year":"2013","unstructured":"Asao K, McHugh JB, Miller DC, Esfandiari NH (2013) Hypercalcemia in upper urinary tract urothelial carcinoma: a case report and literature review. Case Rep Endocrinol 2013:470890","journal-title":"Case Rep Endocrinol"},{"key":"6765_CR23","doi-asserted-by":"publisher","first-page":"rjaa574","DOI":"10.1093\/jscr\/rjaa574","volume":"2021","author":"I Jandou","year":"2021","unstructured":"Jandou I, Wichou E, Ettanji A, Moataz A, Mohammed D, Debbagh A et al (2021) Hypercalcemia an exceptional complication in upper urinary tract urothelial carcinoma. J Surg Case Rep 2021:rjaa574","journal-title":"J Surg Case Rep"},{"key":"6765_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/JCO.20.00979","volume":"39","author":"IE 24 Ahn","year":"2021","unstructured":"Ahn IE, Tian X, Ipe D, Cheng M, Albitar M, Tsao LC et al (2021) Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. J Clin Oncol 39:576\u2013585","journal-title":"J Clin Oncol"},{"key":"6765_CR25","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1186\/s12885-023-11333-z","volume":"23","author":"F 25 Wang","year":"2023","unstructured":"Wang F, Cui S, Lu L, Shao X, Yan F, Liu Y et al (2023) Dissemination feature based on PET\/CT is a risk factor for diffuse large B cell lymphoma patients outcome. BMC Cancer 23:1165","journal-title":"BMC Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06765-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06765-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06765-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:07:38Z","timestamp":1789139258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06765-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6765"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06765-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of the Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (approval number: 2024246NI-(2)), as well as that of each participating institution.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from participants or deceased patients\u2019 families, using the opt-out method because of the retrospective nature of the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"657"}}